You are here

Gilead ordered to pay Merck US$200m for hepatitis C patents

The award against the drugmaker comes amid projections that its sales will flatten this year

36940875.2 (37890478) - 27_03_2016 - HOLD FOR SF CHRONICLE STORY.jpg
Gilead Sciences Inc was ordered by a jury to pay Merck & Co US$200 million for patent infringement over a drug compound that cures hepatitis C, a tenth of what Merck sought.

San Jose

GILEAD Sciences Inc was ordered by a jury to pay Merck & Co US$200 million for patent infringement over a drug compound that cures hepatitis C, a tenth of what Merck sought.

The verdict announced on Thursday follows an earlier finding by the jury embracing Merck's

sentifi.com

Market voices on: